Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) EBITDA (2016 - 2025)

Historic EBITDA for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to -$116.9 million.

  • Agios Pharmaceuticals' EBITDA fell 1367.36% to -$116.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$475.6 million, marking a year-over-year decrease of 1685.94%. This contributed to the annual value of -$425.7 million for FY2024, which is 874.87% down from last year.
  • Agios Pharmaceuticals' EBITDA amounted to -$116.9 million in Q3 2025, which was down 1367.36% from -$127.1 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year EBITDA high stood at -$90.6 million for Q1 2023, and its period low was -$127.1 million during Q2 2025.
  • For the 5-year period, Agios Pharmaceuticals' EBITDA averaged around -$101.9 million, with its median value being -$100.9 million (2023).
  • Per our database at Business Quant, Agios Pharmaceuticals' EBITDA tumbled by 11118.96% in 2021 and then soared by 1041.28% in 2023.
  • Agios Pharmaceuticals' EBITDA (Quarter) stood at -$104.8 million in 2021, then rose by 5.39% to -$99.2 million in 2022, then decreased by 7.16% to -$106.3 million in 2023, then dropped by 17.65% to -$125.0 million in 2024, then rose by 6.53% to -$116.9 million in 2025.
  • Its EBITDA stands at -$116.9 million for Q3 2025, versus -$127.1 million for Q2 2025 and -$106.6 million for Q1 2025.